Glucotrack Has More Data for Implantable Blood Glucose Monitor

Glucotrack has completed a second long-term, preclinical study for its Continuous Blood Glucose Monitor (CBGM).
 
The CBGM measures glucose in the blood without lag time related to subcutaneous sensors that measure glucose in interstitial fluid.
 
The study validated the CBGM’s performance with a Mean Absolute Relative Difference (MARD) of 4.7% at day 90. According to the Rutherford, N.J.-based company, this is considered highly accurate for a continuous glucose monitor (CGM).
 
MARD assesses glucose monitoring devices’ accuracy, measuring the average difference between the CBGM’s measurement and a reference measurement usually obtained from capillary blood glucose. Lower values demonstrate better performance.
 
The 90-day preclinical study had more animal subjects and longer duration than the initial study announced earlier this year. It incorporated periodic glucose tolerance testing to compare the Glucotrack CBGM’s performance against both a commercially available blood glucose monitor and subcutaneous CGM.
 
The study yielded no significant adverse effects. The company plans to begin human clinical trials later this year.
 
“We are again very pleased with the performance of our sensor during a long-term preclinical study and look forward to moving into human clinical trials,” said Glucotrack CEO Paul Goode, Ph.D. “Our CBGM’s ability to continuously measure blood glucose for 2+ years with accuracy, minimal calibration and without a wearable device represents a significant advancement in glucose monitoring. We believe this technology has the potential to greatly improve the quality of life for people with diabetes by providing a more convenient and discreet monitoring solution.”